Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong.
Department of Surgery, Queen Mary Hospital, Hong Kong.
Hong Kong Med J. 2020 Dec;26(6):486-491. doi: 10.12809/hkmj198203. Epub 2020 Dec 4.
Incidence of ductal carcinoma in situ (DCIS) has increased in recent decades because of breast cancer screening. This study comprised a long-term survival analysis of DCIS using 10-year territory-wide data from the Hong Kong Cancer Registry.
This study included all patients diagnosed with DCIS in Hong Kong from 1997 to 2006. Exclusion criteria were age <30 years or ≥70 years, lobular carcinoma in situ, Paget's disease, and co-existing invasive carcinoma. Patients were stratified into those diagnosed from 1997 to 2001 and those diagnosed from 2002 to 2006. The 5- and 10-year breast cancer-specific survival rates were evaluated; standardised mortality ratios were calculated.
Among the 1391 patients in this study, 449 were diagnosed from 1997 to 2001, and 942 were diagnosed from 2002 to 2006. The mean age at diagnosis was 49.2±9.2 years. Overall, 51.2% of patients underwent mastectomy and 29.5% received adjuvant radiotherapy. The median follow-up interval was 11.6 years; overall breast cancer-specific mortality rates were 0.3% and 0.9% after 5 and 10 years of follow-up, respectively. In total, 109 patients (7.8%) developed invasive breast cancer after a considerable delay. Invasive breast cancer rates were comparable between patients diagnosed from 1997 to 2001 (n=37, 8.2%) and those diagnosed from 2002 to 2006 (n=72, 7.6%).
Despite excellent long-term survival among patients with DCIS, these patients were more likely to die of breast cancer, compared with the general population of women in Hong Kong.
由于乳腺癌筛查的普及,近年来导管原位癌(DCIS)的发病率有所上升。本研究利用香港癌症登记处的 10 年全港数据对 DCIS 进行了长期生存分析。
本研究纳入了 1997 年至 2006 年期间在香港诊断为 DCIS 的所有患者。排除标准为年龄<30 岁或≥70 岁、小叶原位癌、派杰氏病和同时存在浸润性癌。患者分为 1997 年至 2001 年诊断和 2002 年至 2006 年诊断两组。评估了 5 年和 10 年乳腺癌特异性生存率;计算了标准化死亡率比。
本研究共纳入 1391 例患者,其中 449 例患者于 1997 年至 2001 年诊断,942 例患者于 2002 年至 2006 年诊断。诊断时的平均年龄为 49.2±9.2 岁。总体而言,51.2%的患者接受了乳房切除术,29.5%的患者接受了辅助放疗。中位随访时间为 11.6 年;随访 5 年和 10 年后,乳腺癌特异性死亡率分别为 0.3%和 0.9%。共有 109 例(7.8%)患者在相当长的时间后发展为浸润性乳腺癌。1997 年至 2001 年诊断(n=37,8.2%)和 2002 年至 2006 年诊断(n=72,7.6%)患者的浸润性乳腺癌发生率相当。
尽管 DCIS 患者的长期生存情况良好,但与香港女性普通人群相比,这些患者死于乳腺癌的风险更高。